A Phase 2 interventional study of gemcitabine and cisplatin in Ovarian Cancer, sponsored by Eli Lilly and Company. Completed at 5 sites in Russian Federation. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-27.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing gemcitabine in Ovarian Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Gemcitabine · Ovarian Neoplasms.
Among the 40 studies testing gemcitabine in Ovarian Neoplasms, this one is the 12th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2004, is one of 21 in phase 2, and was the 17th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →None of the 40 studies testing gemcitabine in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 7
First in 1998; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is close to the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 39 across the 34 interventional studies. Of the 34 that completed or were terminated, 12 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 40 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
29 studies in Ovarian Neoplasms by Eli Lilly and Company: 6 open now, 9 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 29 studies in Ovarian Neoplasms by Eli Lilly and Company, this one is the 23rd largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2004, is one of 14 in phase 2, and was the 6th registered.
Eli Lilly and Company’s Ovarian Neoplasms studies by the year they started, since 1998.
1 of the studies testing gemcitabine in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01970722City of Hope Medical CenterSurgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | 2027-01-05 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing gemcitabine in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 29 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The primary endpoint of this study is to assess the objective tumor response rate in patients with advanced epithelial ovarian cancer receiving combination of Gemcitabine at a dose 1250 mg/m2 (Day 1 and 8) with Cisplatin 75 mg/m2 (Day 1) as first-line treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: gemcitabine · Drug: cisplatin
1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
Also known as: LY188011, Gemzar
75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
Best Overall Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).
Time frame: every other 21 day cycle (6-8 cycles), every 3 months during long-term follow-up
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: every other 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up
Time to Progressive Disease
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
Time frame: every other 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up
Time to Treatment Failure
Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.
Time frame: every other 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up
Number of Patients With Maximum Common Toxicity Criteria - National Cancer Institute (CTC-NCI): Possibly Related to Study Drug by Grade
Grades range from 0 (no toxicity) to 4 (life-threatening or disabling).
Time frame: every 21 day cycle (6-8 cycles) and every 3 months during long-term follow-up
| Milestone | Gemcitabine + Cisplatin |
|---|---|
| Started | 50 |
| Completed | 33 |
| Not completed | 17 |
| Withdrew: Adverse event | 4 |
| Withdrew: Disease progression or relapse | 8 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 4 |
Best response recorded from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).
| participants | Gemcitabine + Cisplatin |
|---|---|
| Complete Response | 6 |
| Partial Response | 25 |
| Stable Disease | 10 |
| Progressive Disease | 5 |
| Not Assessed | 4 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
| weeks | Gemcitabine + Cisplatin |
|---|---|
| Duration of Response | 37.0 (31.1 to 51.1) |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
| weeks | Gemcitabine + Cisplatin |
|---|---|
| Time to Progressive Disease | 45.1 (37.9 to 56.9) |
Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.
| weeks | Gemcitabine + Cisplatin |
|---|---|
| Time to Treatment Failure | 38.4 (29.1 to 48.3) |
Grades range from 0 (no toxicity) to 4 (life-threatening or disabling).
| participants | Gemcitabine + Cisplatin |
|---|---|
| Patients with at least one CTC - Grade 1 | 34 |
| Patients with at least one CTC - Grade 2 | 6 |
| Patients with at least one CTC - Grade 3 | 2 |
| Patients with at least one CTC - Grade 4 | 1 |
| Other auditory/hearing - Grade 1 | 0 |
| Other auditory/hearing - Grade 2 | 0 |
| Other auditory/hearing - Grade 3 | 1 |
| Other auditory/hearing - Grade 4 | 0 |
| Leukocytes - Grade 1 | 0 |
| Leukocytes - Grade 2 | 0 |
| Leukocytes - Grade 3 | 0 |
| Leukocytes - Grade 4 | 1 |
| Neutrophils/granulocytes - Grade 1 | 0 |
| Neutrophils/granulocytes - Grade 2 | 0 |
| Neutrophils/granulocytes - Grade 3 | 0 |
| Neutrophils/granulocytes - Grade 4 | 1 |
| Fatigue - Grade 1 | 11 |
| Fatigue - Grade 2 | 0 |
| Fatigue - Grade 3 | 1 |
| Fatigue - Grade 4 | 0 |
| Weight loss - Grade 1 | 0 |
| Weight loss - Grade 2 | 1 |
| Weight loss - Grade 3 | 0 |
| Weight loss - Grade 4 | 0 |
| Alopecia - Grade 1 | 1 |
| Alopecia - Grade 2 | 1 |
| Alopecia - Grade 3 | 0 |
| Alopecia - Grade 4 | 0 |
| Rash/desquamation - Grade 1 | 2 |
| Rash/desquamation - Grade 2 | 0 |
| Rash/desquamation - Grade 3 | 1 |
| Rash/desquamation - Grade 4 | 0 |
| Anorexia - Grade 1 | 1 |
| Anorexia - Grade 2 | 0 |
| Anorexia - Grade 3 | 0 |
| Anorexia - Grade 4 | 0 |
| Diarrhea (without colostomy) - Grade 1 | 0 |
| Diarrhea (without colostomy) - Grade 2 | 0 |
| Diarrhea (without colostomy) - Grade 3 | 1 |
| Diarrhea (without colostomy) - Grade 4 | 0 |
| Nausea - Grade 1 | 29 |
| Nausea - Grade 2 | 2 |
| Nausea - Grade 3 | 0 |
| Nausea - Grade 4 | 0 |
| Other Gastrointestinal - Grade 1 | 0 |
| Other Gastrointestinal - Grade 2 | 1 |
| Other Gastrointestinal - Grade 3 | 0 |
| Other Gastrointestinal - Grade 4 | 0 |
| Stomatitis/pharyngitis - Grade 1 | 0 |
| Stomatitis/pharyngitis - Grade 2 | 0 |
| Stomatitis/pharyngitis - Grade 3 | 1 |
| Stomatitis/pharyngitis - Grade 4 | 0 |
| Vomiting - Grade 1 | 24 |
| Vomiting - Grade 2 | 0 |
| Vomiting - Grade 3 | 0 |
| Vomiting - Grade 4 | 0 |
| Alkaline phosphatase - Grade 1 | 13 |
| Alkaline phosphatase - Grade 2 | 1 |
| Alkaline phosphatase - Grade 3 | 0 |
| Alkaline phosphatase - Grade 4 | 0 |
| Bilirubin - Grade 1 | 6 |
| Bilirubin - Grade 2 | 0 |
| Bilirubin - Grade 3 | 0 |
| Bilirubin - Grade 4 | 0 |
| Serum glutamic oxaloacetic transaminase - Grade 1 | 8 |
| Serum glutamic oxaloacetic transaminase - Grade 2 | 0 |
| Serum glutamic oxaloacetic transaminase - Grade 3 | 0 |
| Serum glutamic oxaloacetic transaminase - Grade 4 | 0 |
| Serum glutamic pyruvic transaminase - Grade 1 | 7 |
| Serum glutamic pyruvic transaminase - Grade 2 | 0 |
| Serum glutamic pyruvic transaminase - Grade 3 | 0 |
| Serum glutamic pyruvic transaminase - Grade 4 | 0 |
| Dizziness/lightheadedness - Grade 1 | 1 |
| Dizziness/lightheadedness - Grade 2 | 0 |
| Dizziness/lightheadedness - Grade 3 | 0 |
| Dizziness/lightheadedness - Grade 4 | 0 |
| Headache - Grade 1 | 0 |
| Headache - Grade 2 | 1 |
| Headache - Grade 3 | 0 |
| Headache - Grade 4 | 0 |
| Creatinine - Grade 1 | 7 |
| Creatinine - Grade 2 | 1 |
| Creatinine - Grade 3 | 0 |
| Creatinine - Grade 4 | 0 |
| Renal failure - Grade 1 | 0 |
| Renal failure - Grade 2 | 0 |
| Renal failure - Grade 3 | 1 |
| Renal failure - Grade 4 | 0 |
| Renal/genitourinary - Other - Grade 1 | 6 |
| Renal/genitourinary - Other - Grade 2 | 2 |
| Renal/genitourinary - Other - Grade 3 | 1 |
| Renal/genitourinary - Other - Grade 4 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine + Cisplatin | — | — | — |
| Event | Gemcitabine + Cisplatin |
|---|---|
| LeukopeniaBlood and lymphatic system disorders | 1/50 |
| NeutropeniaBlood and lymphatic system disorders | 1/50 |
| DeafnessEar and labyrinth disorders | 1/50 |
| Renal failure acuteRenal and urinary disorders | 1/50 |
| Event | Gemcitabine + Cisplatin |
|---|---|
| NauseaGastrointestinal disorders | 32/50 |
| VomitingGastrointestinal disorders | 25/50 |
| AstheniaGeneral disorders | 17/50 |
| Blood alkaline phosphatase increasedInvestigations | 15/50 |
| Aspartate aminotransferase increasedInvestigations | 14/50 |
| Weight decreasedInvestigations | 11/50 |
| Blood creatinine increasedInvestigations | 10/50 |
| Alanine aminotransferase increasedInvestigations | 9/50 |
| Creatinine renal clearance decreasedInvestigations | 9/50 |
| Weight increasedInvestigations | 9/50 |
| Age Continuous(years) | Gemcitabine + Cisplatin |
|---|---|
| Mean | 54.9 ± 10.7 |
| Sex: Female, Male(Participants) | Gemcitabine + Cisplatin |
|---|---|
| Female | 50 |
| Male | 0 |
| Region of Enrollment(participants) | Gemcitabine + Cisplatin |
|---|---|
| Russian Federation | 50 |
| Disease Stage(participants) | Gemcitabine + Cisplatin |
|---|---|
| Stage I - Tumor Limited to Ovaries | 0 |
| Stage II - Pelvic Extension and/or Implants | 0 |
| Stage IIIa - Microscopic Peritoneal Metastasis | 1 |
| Stage IIIb - Macroscopic Peritoneal Metastasis | 3 |
| Stage IIIc - Peritoneal Metastasis More Than 2 cm | 21 |
| Stage IV - Distant Metastases | 25 |
| Eastern Cooperative Oncology Group Performance Status Score(participants) | Gemcitabine + Cisplatin |
|---|---|
| 0 - Fully Active | 28 |
| 1 - Ambulatory, Restricted Strenuous Activity | 20 |
| 2 - Ambulatory, No Work Activities | 2 |
| 3 - Partially Confined to Bed, Limited Self Care | 0 |
| 4 - Completely Disabled | 0 |
| Postoperational Pathomorphological Diagnosis(participants) | Gemcitabine + Cisplatin |
|---|---|
| Serous Cystadenocarcinoma | 37 |
| Mucinosa Cystadenocarcinoma | 3 |
| Endometrioid Carcinoma | 4 |
| Other | 6 |
| Race/Ethnicity(participants) | Gemcitabine + Cisplatin |
|---|---|
| Caucasian | 49 |
| Other | 1 |
| State of Patient Relative to Menopause(participants) | Gemcitabine + Cisplatin |
|---|---|
| Fertile Period | 4 |
| Post-Menopause | 46 |
1 further baseline measures are reported on the registry.
The record gives a start of Dec 2004, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Cisplatin